Sign in

You're signed outSign in or to get full access.

VM

Vivani Medical, Inc. (VANI)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 was operationally on track: LIBERATE-1 enrollment completed quickly and “all NPM-115 insertions were successful,” with top-line data still expected mid-2025 .
  • Preclinical progress broadened the pipeline: NPM-139 (semaglutide implant) showed ~20% placebo-adjusted weight loss in rats and durable PK supporting potential once-yearly dosing .
  • Balance sheet strengthened: an additional $3.0M private placement and prior $8.25M financing extended cash runway to mid-2026, slightly improved from Q4’s “into the second quarter of 2026” guidance .
  • Strategic catalyst: Vivani intends to spin off Cortigent by or before Q3 2025, creating two focused companies and potential value unlock .
  • No Wall Street consensus estimates available for Q1 2025; company remains pre-revenue and focused on clinical execution, making mid-2025 LIBERATE-1 data the key near-term stock driver .

What Went Well and What Went Wrong

What Went Well

  • LIBERATE-1 execution: “All NPM-115 (exenatide implant) insertions were successful” and the study “remains on track to deliver key data in mid-2025” .
    • CEO: “Our ongoing first-in-human study, LIBERATE-1, remains on track to deliver key data in mid-2025… The study enrolled ahead of schedule” .
  • Financing runway extended: $3.0M May private placement, plus $8.25M March financing, supports operations into mid-2026 .
  • Pipeline breadth: Positive preclinical data for NPM-139 (semaglutide implant) reinforced the potential for once- or twice-yearly dosing in chronic weight management .

What Went Wrong

  • Cash burn elevated: Net cash used in operating activities was $5.163M in Q1; cash, cash equivalents and restricted cash fell to $14.346M at quarter-end from $19.690M at year-end .
  • Net loss widened YoY: Net loss was $6.302M vs $6.039M in Q1 2024; R&D rose to $4.217M (+13% YoY) reflecting biopharma investments .
  • Legal overhang: Pixium litigation persists with €1.55M judgment on appeal; strike-out order requires reinstatement upon evidence of enforcement or agreement, adding uncertainty .

Financial Results

MetricQ3 2024Q4 2024Q1 2025
Research & Development ($USD Millions)$4.203 $4.297 $4.217
General & Administrative ($USD Millions)$2.106 $2.163 $2.340
Total Operating Expenses ($USD Millions)$6.309 $6.460 $6.557
Other Income (Net) ($USD Millions)$0.268 $0.410 $0.255
Net Loss ($USD Millions)$6.041 $6.050 $6.302
Diluted EPS ($USD)$(0.11) $(0.11) $(0.11)
Cash, Cash Equivalents & Restricted Cash ($USD Millions)$21.0 $19.7 $14.346

Segment breakdown (Q1 2025):

SegmentOperating Expenses ($USD Millions)Other Income (Expense), Net ($USD Millions)Segment Net Loss ($USD Millions)
Biopharm Division$6.0 (component detail in table) $(0.296) $5.645
Neuromodulation Division$0.6 (component detail in table) $0.041 $0.657

KPIs:

KPIQ3 2024Q4 2024Q1 2025
LIBERATE-1 statusRegulatory approvals to initiate; financing to complete Initial administration successful; full enrollment; mid-2025 top-line expected All implant insertions successful; mid-2025 top-line maintained
Biopharm headcount—35 FTEs —
Cash runway guidanceLate 2025 Into Q2 2026 Into mid-2026

Note: Vivani remains pre-revenue (“The Company has not generated any product revenue to date”) .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
LIBERATE-1 top-line data timingMid-2025Mid-2025 (maintained) Mid-2025 Maintained
Cash runwayThrough 2026Into Q2 2026 Into mid-2026 Slightly extended
Cortigent spin-offCompletion timingDuring or prior to Q3 2025 During or prior to Q3 2025 (plan reiterated) Maintained

Earnings Call Themes & Trends

TopicQ3 2024 (Previous)Q4 2024 (Previous)Q1 2025 (Current)Trend
GLP-1 program progress (NPM-115)Regulatory approval to initiate LIBERATE-1 in Australia Initial administration and full enrollment; mid-2025 data All insertions successful; mid-2025 data On track / de-risking
Financing runway$5M financing; runway into late 2025 $8.25M financing; runway into Q2 2026 $3.0M financing; runway into mid-2026 Improving
NPM-139 (semaglutide implant)—Positive preclinical weight loss data; once-yearly potential Additional preclinical support for once/twice-yearly dosing Accelerating
Cortigent spin-off——Intent to spin off; target by/before Q3 2025 New strategic path
Veterinary GLP-1 (Okava)——Expanded collaboration to dogs (OKV-119) Adjacent market optionality
Macro/tariff risk disclosures——Expanded risk language re tariffs/geopolitics Cautionary backdrop

Note: No Q1 2025 earnings call transcript was available; Vivani hosted an investor call on March 13 related to LIBERATE-1 enrollment (link provided), but no transcript was provided .

Management Commentary

  • CEO (Adam Mendelsohn): “Our ongoing first-in-human study, LIBERATE-1, remains on track to deliver key data in mid-2025… The study enrolled ahead of schedule, and all NPM-115 (exenatide implant) insertions were successful.”
  • CEO: “We remain confident that our emerging portfolio of convenient, miniature, subdermal drug implants with once- or twice-yearly dosing will stand out… with the potential to substantially improve patient outcomes by addressing poor medication adherence and patient tolerability.”
  • On financing: $3M May placement together with the $8.25M March placement “secures financial position into mid-2026.”

Q&A Highlights

  • No formal Q1 2025 earnings call transcript was available to review; Vivani did host an investor call March 13 regarding LIBERATE-1 milestones, but a transcript was not furnished .

Estimates Context

  • S&P Global consensus EPS and revenue estimates for Q1 2025 were unavailable; we attempted retrieval and found no values. Values retrieved from S&P Global.*
  • Vivani provided no quantitative revenue/EPS guidance and remains pre-revenue, so mid-2025 clinical data (LIBERATE-1) is the primary driver for potential estimate revisions and narrative shifts .

Key Takeaways for Investors

  • The clinical execution box is being checked: LIBERATE-1 is fully enrolled with successful implant insertions; mid-2025 top-line is a near-term binary catalyst likely to move the stock .
  • Bold: Financing runway extended to mid-2026 reduces near-term dilution risk and supports continued development across NPM-115 and NPM-139 .
  • Pipeline breadth adds upside optionality: NPM-139 preclinical data supports potential once-yearly dosing, expanding narrative beyond exenatide .
  • Strategic separation: The Cortigent spin-off (target completion by/before Q3 2025) could clarify value and reduce conglomerate discount .
  • Watch cash burn: Operating cash outflow was $5.163M in Q1; sustained R&D intensity implies continued need for disciplined capital deployment .
  • Legal overhang persists: Pixium matter is ongoing and may require resolution steps; monitor for updates given strike-out order and appeal pathway .
  • Pre-revenue profile: Absent consensus estimates and revenue, trading will hinge on clinical milestones, financing cadence, and strategic updates—particularly mid-2025 LIBERATE-1 data .